ICP-332 in Subjects With Non-segmental Vitiligo

Summary

This a phase II/III randomized, double-blind, placebo-controlled, parallel group, adaptive design, multi-center study to evaluate the efficacy and safety of ICP-332 in subjects with non-segmental vitiligo。The study consisted an phase 2 part and an phase 3 part.

Timeline

Start

2025-05-09

Primary completion

2029-04

Completion

2029-04

Drugs

Indications